Professional Summary »
Specializing In »
Practice Locations »
Referring Physicians »
Biography
Dr. Guido A. Davidzon is a physician-scientist board certified in Nuclear Medicine. He is an attending physician in Nuclear Medicine and Molecular Imaging at Stanford Health Care. He graduated with honors from medical school in Argentina and completed an internship at Yale University New-Haven Hospital in Connecticut. He did his residency and was chief resident at Stanford Health Care. He completed a research fellowship in mitochondrial diseases at Columbia University in New York and, a U.S. National Library of Medicine Award supported, Biomedical Informatics fellowship at Massachusetts General Hospital in conjunction with a Science Masters at MIT.
Dr. Davidzon is a Clinical Associate Professor in the Department of Radiology at Stanford University. His clinical specialties include early diagnostic imaging of cancer, coronary artery disease, and dementias using molecular probes as well as the treatment of cancer for which he employs targeted radiopharmaceutical therapy.
At present, Dr. Davidzon is President of the Northern Chapter of the SNMMI. He is a faculty member at the Center for Artificial Intelligence in Medicine & Imaging and leads machine learning efforts for the Nuclear Medicine & Molecular Imaging Division. Dr. Davidzon steers the Cardiac Stress PET Clinical Program at Stanford that provides quantification of myocardial blood flow to assess epicardial and microvascular coronary circulation. He is the director of the DXA program at SHC and an active member of the Diversity Initiative Committee in Radiology. Dr. Davidzon is a native of Buenos Aires, Argentina, and has lived in the U.S. for over a decade.
Dr. Davidzon is a Clinical Associate Professor in the Department of Radiology at Stanford University. His clinical specialties include early diagnostic imaging of cancer, coronary artery disease, and dementias using molecular probes as well as the treatment of cancer for which he employs targeted radiopharmaceutical therapy.
At present, Dr. Davidzon is President of the Northern Chapter of the SNMMI. He is a faculty member at the Center for Artificial Intelligence in Medicine & Imaging and leads machine learning efforts for the Nuclear Medicine & Molecular Imaging Division. Dr. Davidzon steers the Cardiac Stress PET Clinical Program at Stanford that provides quantification of myocardial blood flow to assess epicardial and microvascular coronary circulation. He is the director of the DXA program at SHC and an active member of the Diversity Initiative Committee in Radiology. Dr. Davidzon is a native of Buenos Aires, Argentina, and has lived in the U.S. for over a decade.
View Full Biography »
Professional Summary
Education & Certifications
- Board Certification: American Board of Nuclear Medicine, Nuclear Medicine (2013)
- Residency: Stanford Health Services - Fellowship/Diagnostic Radiology (2013) CA
- Fellowship, Massachusetts General Hospital - LCS, Clinical Informatics (2010)
- SM, Massachusetts Institute of Technology, Biomedical Informatics (2010)
- Internship: Yale - New Haven Hospital (2007) CT
- Fellowship, Columbia University, Mitochondrial Genetic Disorders (2006)
- MD with Honors, Universidad Maimonides, Argentina, Doctor in Medicine (2003)
Awards & Memberships
- Best Abstract Award Young Professionals Competition 2nd Sino-American Conference, SNMMI/CSNM (1/2013)
- Best Essay Travel Award, SNMMI/ACNM (1/2012)
- First SNMMI Emerging Leader Award, SMMMI (6/2017)
- Future Leaders Academy Award, SNMMI (1/2015)
- Nuclear Oncology Council Young Investigator Award, SNMMI (6/2011)
Administrative Appointments
- Alt Member, Clinical Radiation Safety Committee (2017 - Present)
- Director, DXA Imaging Program (2017 - Present)
- Interim Lead, Targeted Radionuclide Therapy Program (2017 - 2018)
- Lead, Cardiac Stress PET Program (2020 - Present)
- Lead, Machine Learning in NM & Molecular Imaging (2020 - Present)
Publications
-
Prognostic PET F-18-FDG Uptake Imaging Features Are Associated with Major Oncogenomic Alterations in Patients with Resected Non-Small Cell Lung Cancer
Nair, V. S., Gevaert, O., Davidzon, G., Napel, S., Graves, E. E., Hoang, C. D., … Plevritis, S. K. (2012). Prognostic PET F-18-FDG Uptake Imaging Features Are Associated with Major Oncogenomic Alterations in Patients with Resected Non-Small Cell Lung Cancer. CANCER RESEARCH, 72(15), 3725–34. -
NF-?B protein expression associates with (18)F-FDG PET tumor uptake in non-small cell lung cancer: A radiogenomics validation study to understand tumor metabolism.
Nair, V. S., Gevaert, O., Davidzon, G., Plevritis, S. K., & West, R. (2014). NF-?B protein expression associates with (18)F-FDG PET tumor uptake in non-small cell lung cancer: A radiogenomics validation study to understand tumor metabolism. Lung Cancer , 83(2), 189–96. -
Case 207: Hodgkin lymphoma with paraneoplastic hypercalcemic pancreatitis.
Mittra, E. S., & Davidzon, G. (2014). Case 207: Hodgkin lymphoma with paraneoplastic hypercalcemic pancreatitis. Radiology, 272(1), 296–300. -
A Clinical Database-Driven Approach to Decision Support: Predicting Mortality Among Patients with Acute Kidney Injury
Celi, L. A. G., Tang, R. J., Villarroel, M. C., Davidzon, G. A., Lester, W. T., & Chueh, H. C. (2011). A Clinical Database-Driven Approach to Decision Support: Predicting Mortality Among Patients with Acute Kidney Injury. JOURNAL OF HEALTHCARE ENGINEERING, 2(1), 97–109. -
A Database-driven Decision Support System: Customized Mortality Prediction.
Celi, L. A., Galvin, S., Davidzon, G., Lee, J., Scott, D., & Mark, R. (2012). A Database-driven Decision Support System: Customized Mortality Prediction. Journal of Personalized Medicine, 2(4), 138–48. -
FDG-PET/CT Initial and Subsequent Therapy Evaluation: Progressing to PET/MR Imaging.
Mosci, C., Davidzon, G. A., & Quon, A. (2012). FDG-PET/CT Initial and Subsequent Therapy Evaluation: Progressing to PET/MR Imaging. PET Clinics, 7(4), 369–80. -
Neutral lipid storage disease with subclinical myopathy due to a retrotransposal insertion in the PNPLA2 gene
Akman, H. O., Davidzon, G., Tanji, K., MacDermott, E. J., Larsen, L., Davidson, M. M., … DiMauro, S. (2010). Neutral lipid storage disease with subclinical myopathy due to a retrotransposal insertion in the PNPLA2 gene. NEUROMUSCULAR DISORDERS, 20(6), 397–402. -
Intracerebral Periventricular Pseudocysts in a Fetus with Mitochondrial Depletion Syndrome: An Association or Coincidence
Rohrbach, M., Chitayat, D., Maegawa, G., Shanske, S., Davidzon, G., Chong, K., … Blaser, S. (2009). Intracerebral Periventricular Pseudocysts in a Fetus with Mitochondrial Depletion Syndrome: An Association or Coincidence. FETAL DIAGNOSIS AND THERAPY, 25(2), 177–182. -
SemanticDx: a prototype to facilitate use of biostatistics at the point-of-care.
Davidzon, G., Pankey, E., Loudon, T., Schmid, P., Berger, B., & Berkowicz, D. (2008). SemanticDx: a prototype to facilitate use of biostatistics at the point-of-care. AMIA ... Annual Symposium Proceedings / AMIA Symposium. AMIA Symposium, 921-? -
Progressive external ophthalmoplegia and vision and hearing loss in a patient with mutations in POLG2 and OPA1
Ferraris, S., Clark, S., Garelli, E., Davidzon, G., Moore, S. A., Kardon, R. H., … DiMauro, S. (2008). Progressive external ophthalmoplegia and vision and hearing loss in a patient with mutations in POLG2 and OPA1. ARCHIVES OF NEUROLOGY, 65(1), 125–31. -
Juvenile Alpers disease
Wiltshire, E., Davidzon, G., DiMauro, S., Akman, H. O., Sadleir, L., Haas, L., … Thorburn, D. R. (2008). Juvenile Alpers disease. ARCHIVES OF NEUROLOGY, 65(1), 121–124. -
Autosomal dominant psychiatric disorders and mitochondrial DNA multiple deletions: Report of a family
Mancuso, M., Ricci, G., Choub, A., Filosto, M., DiMauro, S., Davidzon, G., … Siciliano, G. (2008). Autosomal dominant psychiatric disorders and mitochondrial DNA multiple deletions: Report of a family. JOURNAL OF AFFECTIVE DISORDERS, 106(1-2), 173–177. -
Abundance of the POLG disease mutations in Europe, Australia, New Zealand, and the United States explained by single ancient European founders
Hakonen, A. H., Davidzon, G., Salemi, R., Bindoff, L. A., Van Goethem, G., DiMauro, S., … Suomalainen, A. (2007). Abundance of the POLG disease mutations in Europe, Australia, New Zealand, and the United States explained by single ancient European founders. EUROPEAN JOURNAL OF HUMAN GENETICS, 15(7), 779–783. -
Severe encephalomyopathy in a patient with homoplasmic A5814G point mutation in mitochondrial tRNA(Cys) gene
Scuderi, C., Borgione, E., Musumeci, S., Elia, M., Castello, F., Fichera, M., … DiMauro, S. (2007). Severe encephalomyopathy in a patient with homoplasmic A5814G point mutation in mitochondrial tRNA(Cys) gene. NEUROMUSCULAR DISORDERS, 17(3), 258–261. -
Clinical spectrum of mitochondrial DNA depletion due to mutations in the thymidine kinase 2 gene
Oskoui, M., Davidzon, G., Pascual, J., Erazo, R., Gurgel-Giannetti, J., Krishna, S., … DiMauro, S. (2006). Clinical spectrum of mitochondrial DNA depletion due to mutations in the thymidine kinase 2 gene. ARCHIVES OF NEUROLOGY, 63(8), 1122–1126. -
A polymorphic polymerase
DiMauro, S., Davidzon, G., & Hirano, M. (2006). A polymorphic polymerase. BRAIN, 129, 1637–1639. -
Early-onset familial Parkinsonism due to POLG mutations
Davidzon, G., Greene, P., Mancuso, M., Klos, K. J., Ahlskog, J. E., Hirano, M., & DiMauro, S. (2006). Early-onset familial Parkinsonism due to POLG mutations. ANNALS OF NEUROLOGY, 59(5), 859–862. -
Mitochondrial DNA and disease
DiMauro, S., & Davidzon, G. (2005). Mitochondrial DNA and disease. ANNALS OF MEDICINE, 37(3), 222–232. -
POLG mutations and Alpers syndrome
Davidzon, G., Mancuso, M., Ferraris, S., Quinzii, C., Hirano, M., Peters, H. L., … DiMauro, S. (2005). POLG mutations and Alpers syndrome. ANNALS OF NEUROLOGY, 57(6), 921–923. -
Hereditary ferritinopathy: A novel mutation, its cellular pathology, and pathogenetic insights
Mancuso, M., Davidzon, G., Kurlan, R. M., Tawil, R., Bonilla, E., Di Mauro, S., & Powers, J. M. (2005). Hereditary ferritinopathy: A novel mutation, its cellular pathology, and pathogenetic insights. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 64(4), 280–294. -
Comparison of four different imaging response criteria in patients with Hodgkin and non-Hodgkin lymphoma using PET/CT
Davidzon, G., & Mittra, E. (2011). Comparison of four different imaging response criteria in patients with Hodgkin and non-Hodgkin lymphoma using PET/CT. Presented at the SNMMI, San Antonio, TX: J Nucl Med. -
Utility of 18F FDG PET/CT in patients with advanced thymic neoplasms
Davidzon, G., Wakelee, H., Neal, J., Mittra, E., Quon, A., & Iagaru, A. (2012). Utility of 18F FDG PET/CT in patients with advanced thymic neoplasms. Presented at the SNMMI, Miami, FL: J Nucl Med. -
Detection of bone marrow disease in lymphoma using computer aided segmentation and analysis
Davidzon, G., Peng, Z., Anand, V., Zhou, X., & Quon, A. (2012). Detection of bone marrow disease in lymphoma using computer aided segmentation and analysis. Presented at the SNMMI, Miami, FL: J Nucl Med. -
Biodistribution and kinetics of 18F FPPRGD2 in cancer patients
Davidzon, G., Mosci, C., MIttra, E., Shen, B., Chin, F., Gambhir, S., & Iagaru, A. (2013). Biodistribution and kinetics of 18F FPPRGD2 in cancer patients. Presented at the SNMMI, Vancouver, Canada: J Nucl Med. -
Bridging the Health Data Divide
Celi, L. A., & Davidzon, G. (2016). Bridging the Health Data Divide. Journal of Medical Internet Research, 18(12). -
L/I-13 Donor hepatectomy morbidity based on the Clavien scale
Kinkhabwala, M., Davidzon, G., Lapointe, R., Brown, R., & Emond, J. (2006). L/I-13 Donor hepatectomy morbidity based on the Clavien scale. Clinical Transplantation, 20. -
18F-FDG silicon photomultiplier PET/CT: A pilot study comparing semi-quantitative measurements with standard PET/CT.
Baratto, L., Park, S. Y., Hatami, N., Davidzon, G., Srinivas, S., Gambhir, S. S., & Iagaru, A. (2017). 18F-FDG silicon photomultiplier PET/CT: A pilot study comparing semi-quantitative measurements with standard PET/CT. PloS One, 12(6). -
Initial Experience with a SiPM-based PET/CT Scanner: Influence of Acquisition Time on Image Quality
Sonni, I., Park, S., Baratto, L., Hatami, N., Davidzon, G., Srinivas, S., … Iagaru, A. (2017). Initial Experience with a SiPM-based PET/CT Scanner: Influence of Acquisition Time on Image Quality. JOURNAL OF NUCLEAR MEDICINE, 58. -
Initial Experience with a New PET/CT System Using SiPM Detectors: Image Quality Comparison with Standard PET/CT
Park, S., Baratto, L., Hatami, N., Davidzon, G., Srinivas, S., Gambhir, S., & Lagaru, A. (2017). Initial Experience with a New PET/CT System Using SiPM Detectors: Image Quality Comparison with Standard PET/CT. JOURNAL OF NUCLEAR MEDICINE, 58. -
SiPM PET/CT vs. Standard PET/CT: A Pilot Study Comparing Semi-Quantitative Measurements in Normal Tissues and Lesions
Baratto, L., Park, S., Hatami, N., Davidzon, G., Srinivas, S., Gambhir, S., & Iagaru, A. (2017). SiPM PET/CT vs. Standard PET/CT: A Pilot Study Comparing Semi-Quantitative Measurements in Normal Tissues and Lesions. JOURNAL OF NUCLEAR MEDICINE, 58. -
Biodistribution and kinetics of 18F FPPRGD2 in cancer patients
Davidzon, G., Mosci, C., Mittra, E., Shen, B., Chin, F., Gambhir, S., & Iagaru, A. (2013). Biodistribution and kinetics of 18F FPPRGD2 in cancer patients. JOURNAL OF NUCLEAR MEDICINE, 54. -
Pilot Prospective Evaluation of Early Response to Bevacizumab Treatment Using the Novel PET/CT Radiopharmaceutical 18F FPPRGD2
Iagaru, A., Mosci, C., Davidzon, G., Kumar, M., Shen, B., Chin, F., & Gambhir, S. S. (2013). Pilot Prospective Evaluation of Early Response to Bevacizumab Treatment Using the Novel PET/CT Radiopharmaceutical 18F FPPRGD2. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 40, S185. -
Initial experience with a SiPM-based PET/CT scanner: influence of acquisition time on image quality
Sonni, I., Baratto, L., Park, S., Hatami, N., Srinivas, S., Davidzon, G., … Iagaru, A. (2018). Initial experience with a SiPM-based PET/CT scanner: influence of acquisition time on image quality. EJNMMI PHYSICS, 5, 9. -
Comparison Between Different PET and CT-Based Imaging Interpretation Criteria at Interim Imaging in Patients With Diffuse Large B-Cell Lymphoma
Baratto, L., Davidzon, G. A., Moghbel, M., Hatami, N., Iagaru, A., & Mittra, E. S. (2018). Comparison Between Different PET and CT-Based Imaging Interpretation Criteria at Interim Imaging in Patients With Diffuse Large B-Cell Lymphoma. CLINICAL NUCLEAR MEDICINE, 43(1), 1–8. -
Dual-Time Ga-68-RM2 Imaging for Staging Patients with Newly Diagnosed Intermediate or High Risk Prostate Cancer Using PMT and SiPM-Based Detectors PET/CT
Baratto, L., Duan, H., Hatami, N., Yohannan, T., Mari, C., Davidzon, G., & Iagaru, A. (2018). Dual-Time Ga-68-RM2 Imaging for Staging Patients with Newly Diagnosed Intermediate or High Risk Prostate Cancer Using PMT and SiPM-Based Detectors PET/CT. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 45, S724. -
Ga-68-PSMA-11 Imaging for Biochemical Relapse of Prostate Cancer Using Dual-Time LYSO and SiPM-Based Detectors PET/CT
Duan, H., Park, S., Baratto, L., Hatami, N., Khalaf, M. H., Yohannan, T. K., … Iagaru, A. H. (2018). Ga-68-PSMA-11 Imaging for Biochemical Relapse of Prostate Cancer Using Dual-Time LYSO and SiPM-Based Detectors PET/CT. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 45, S713. -
Ga-68-RM2 PET/MRI Detection of Recurrent Prostate Cancer in Patients with Negative Conventional Imaging
Baratto, L., Duan, H., Harrison, C., Mari, C., Davidzon, G., Yohannan, T., & Iagaru, A. (2018). Ga-68-RM2 PET/MRI Detection of Recurrent Prostate Cancer in Patients with Negative Conventional Imaging. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 45, S151–S152. -
Ga-68-RM2 PET vs. Ga-68-PSMA-11 PET: Prospective Comparison in Patients with Biochemical Recurrence of Prostate Cancer
Baratto, L., Duan, H., Minamimoto, R., Mari, C., Yohannan, T., Davidzon, G., & Iagaru, A. (2018). Ga-68-RM2 PET vs. Ga-68-PSMA-11 PET: Prospective Comparison in Patients with Biochemical Recurrence of Prostate Cancer. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 45, S151. -
Positron Emission Tomography (PET) Tumor Penumbra Imaging Features Predict Outcome in Non-Small Cell Lung Cancer
Mattonen, S., Davidzon, G. A., Bakr, S., Vasanawala, M., Horng, G. S., Napel, S., & Nair, V. S. (2018). Positron Emission Tomography (PET) Tumor Penumbra Imaging Features Predict Outcome in Non-Small Cell Lung Cancer. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 197. -
A study to evaluate immunological response to PD-1 inhibition in squamous cell carcinoma of the head and neck (SCCHN) using novel PET imaging with [18F] F-AraG
Colevas, D. A., Davidzon, G. A., & Sunwoo, J. B. (2018). A study to evaluate immunological response to PD-1 inhibition in squamous cell carcinoma of the head and neck (SCCHN) using novel PET imaging with [18F] F-AraG. JOURNAL OF CLINICAL ONCOLOGY, 36(15). -
Embrace Progress
Bradley, K. M., McGowan, D. R., Gleeson, F. V., Johnson, G. B., Young, J. R., Levin, C. S., … Iagaru, A. H. (2018). Embrace Progress. JOURNAL OF NUCLEAR MEDICINE, 59(7), 1169. -
[18F] FDG Positron Emission Tomography (PET) Tumor and Penumbra Imaging Features Predict Recurrence in Non-Small Cell Lung Cancer.
Mattonen, S. A., Davidzon, G. A., Bakr, S., Echegaray, S., Leung, A. N., Vasanawala, M., … Nair, V. S. (2019). [18F] FDG Positron Emission Tomography (PET) Tumor and Penumbra Imaging Features Predict Recurrence in Non-Small Cell Lung Cancer. Tomography (Ann Arbor, Mich.), 5(1), 145–53. -
Utility of 18F FDG PET/CT in patients with advanced thymic neoplasms
Davidzon, G., Wakelee, H., Neal, J., Mittra, E., Quon, A., & Iagaru, A. (2012). Utility of 18F FDG PET/CT in patients with advanced thymic neoplasms. JOURNAL OF NUCLEAR MEDICINE, 53. -
[18F] FDG Positron Emission Tomography (PET) Tumor and Penumbra Imaging Features Predict Recurrence in Non-Small Cell Lung Cancer
Mattonen, S. A., Davidzon, G. A., Bakr, S., Echegaray, S., Leung, A. N. C., Vasanawala, M., … Nair, V. S. (2019). [18F] FDG Positron Emission Tomography (PET) Tumor and Penumbra Imaging Features Predict Recurrence in Non-Small Cell Lung Cancer. TOMOGRAPHY, 5(1), 145–53. -
Integrated Bone Marrow and Tumor Radiomics on [18F] FDG Positron Emission Tomography (PET) Augment Stage for Outcome Prediction in Non-Small Cell Lung Cancer
Mattonen, S. A., Davidzon, G. A., Benson, J. A., Vasanawala, M., Leung, A. N. C., Horng, G. S., … Nair, V. S. (2019). Integrated Bone Marrow and Tumor Radiomics on [18F] FDG Positron Emission Tomography (PET) Augment Stage for Outcome Prediction in Non-Small Cell Lung Cancer. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 199. -
Prognostic value of volumetric parameters calculated from Ga-68-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors
Toriihara, A., Baratto, L., Nobashi, T., Park, S., Hatami, N., Davidzon, G., … Iagaru, A. (2018). Prognostic value of volumetric parameters calculated from Ga-68-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors. JOURNAL OF NUCLEAR MEDICINE, 59. -
Ga-68-RM2 PET/MRI Detection of Recurrent Prostate Cancer in Patients with Negative Conventional Imaging
Baratto, L., Harrison, C., Davidzon, G., Yohannan, T., & Iagaru, A. (2018). Ga-68-RM2 PET/MRI Detection of Recurrent Prostate Cancer in Patients with Negative Conventional Imaging. JOURNAL OF NUCLEAR MEDICINE, 59. -
Preliminary Results of a Prospective Study of Ga-68-RM2 PET/MRI for Detection of Recurrent Prostate Cancer in Patients with Negative Conventional Imaging
Baratto, L., Duan, H., Harrison, C., Hatami, N., Aparici, C. M., Davidzon, G., … Iagaru, A. (2019). Preliminary Results of a Prospective Study of Ga-68-RM2 PET/MRI for Detection of Recurrent Prostate Cancer in Patients with Negative Conventional Imaging. JOURNAL OF NUCLEAR MEDICINE, 60. -
Prospective Evaluation of F-18-DCFPyL PET/CT and Conventional Imaging in Patients with Biochemically Recurrent Prostate Cancer
Song, H., Harrison, C., Guja, K., Franc, B., Moradi, F., Davidzon, G., … Iagaru, A. (2019). Prospective Evaluation of F-18-DCFPyL PET/CT and Conventional Imaging in Patients with Biochemically Recurrent Prostate Cancer. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Comparison of three interpretation criteria of Ga-68-PS A PET based on in er and intra-reader agreement
Toriihara, A., Nobashi, T., Baratto, L., Park, S., Hatami, N., Duan, H., … Iagaru, A. (2019). Comparison of three interpretation criteria of Ga-68-PS A PET based on in er and intra-reader agreement. JOURNAL OF NUCLEAR MEDICINE, 60. -
Prospective Comparison of F-18-DCFPyL PET/CT with F-18-NaF PET/CT for Detection of Skeletal Metastases in Biochemically Recurrent Prostate Cancer
Duan, H., Song, H., Baratto, L., Khalaf, M., Hatami, N., Franc, B., … Iagaru, A. (2019). Prospective Comparison of F-18-DCFPyL PET/CT with F-18-NaF PET/CT for Detection of Skeletal Metastases in Biochemically Recurrent Prostate Cancer. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Prospective evaluation of F-18- DCFPyL in Patients with Biochemically Recurrent Prostate Cancer: Positivity Rate and Correlation with PSA levels
Harrison, C., Song, H., Franc, B. L., Guja, K., Moradi, F., Davidzon, G., … Iagaru, A. (2019). Prospective evaluation of F-18- DCFPyL in Patients with Biochemically Recurrent Prostate Cancer: Positivity Rate and Correlation with PSA levels. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Non-invasive quantification of tau accumulation in dementia using simultaneous F-18-PI-2620 PET/MRI
Fan, A. P., Chen, K. T., Nadiadwala, A., Toueg, T., Sha, S., Greicius, M. D., … Mormino, E. C. (2019). Non-invasive quantification of tau accumulation in dementia using simultaneous F-18-PI-2620 PET/MRI. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 39, 110–11. -
Prognostic value of somatostatin receptor expressing tumor volume calculated from 68Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors.
Toriihara, A., Baratto, L., Nobashi, T., Park, S., Hatami, N., Davidzon, G., … Iagaru, A. (2019). Prognostic value of somatostatin receptor expressing tumor volume calculated from 68Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors. European Journal of Nuclear Medicine and Molecular Imaging. -
F-18-FDG PET/MR Refines Evaluation in Newly Diagnosed Metastatic Urethral Adenocarcinoma
Laudicella, R., Davidzon, G., Vasanawala, S., Baldari, S., & Iagaru, A. (2019). F-18-FDG PET/MR Refines Evaluation in Newly Diagnosed Metastatic Urethral Adenocarcinoma. NUCLEAR MEDICINE AND MOLECULAR IMAGING, 53(4), 296–99. -
18F-FDG PET/MR Refines Evaluation in Newly Diagnosed Metastatic Urethral Adenocarcinoma.
Laudicella, R., Davidzon, G., Vasanawala, S., Baldari, S., & Iagaru, A. (2019). 18F-FDG PET/MR Refines Evaluation in Newly Diagnosed Metastatic Urethral Adenocarcinoma. Nuclear Medicine and Molecular Imaging, 53(4), 296–299. -
SiPM-based vs LYSO-based Ga-68-DOTA-TATE PET/CT: Comparison of Semi-Quantitative Measurements in Normal Tissues and Lesions
Baratto, L., Toriihara, A., Hatami, N., Davidzon, G., Srinivas, S., Gambhir, S., & Iagaru, A. (2018). SiPM-based vs LYSO-based Ga-68-DOTA-TATE PET/CT: Comparison of Semi-Quantitative Measurements in Normal Tissues and Lesions. JOURNAL OF NUCLEAR MEDICINE, 59. -
Bone Marrow and Tumor Radiomics at 18F-FDG PET/CT: Impact on Outcome Prediction in Non-Small Cell Lung Cancer.
Mattonen, S. A., Davidzon, G. A., Benson, J., Leung, A. N., Vasanawala, M., Horng, G., … Nair, V. S. (2019). Bone Marrow and Tumor Radiomics at 18F-FDG PET/CT: Impact on Outcome Prediction in Non-Small Cell Lung Cancer. Radiology, 190357. -
Comparison of three interpretation criteria of 68Ga-PSMA11 PET based on inter- and intra-reader agreement.
Toriihara, A., Nobashi, T., Baratto, L., Duan, H., Moradi, F., Park, S., … Iagaru, A. (2019). Comparison of three interpretation criteria of 68Ga-PSMA11 PET based on inter- and intra-reader agreement. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
Initial experience with a PET/computed tomography system using silicon photomultiplier detectors.
Park, S. Y., Barrato, L., Hatami, N., Davidzon, G., Gambhir, S. S., & Iagaru, A. (2019). Initial experience with a PET/computed tomography system using silicon photomultiplier detectors. Nuclear Medicine Communications. -
Prospective Evaluation in an Academic Center of 18F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer: A Focus on Localizing Disease and Changes in Management.
Song, H., Harrison, C., Duan, H., Guja, K., Hatami, N., Franc, B., … Iagaru, A. (2019). Prospective Evaluation in an Academic Center of 18F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer: A Focus on Localizing Disease and Changes in Management. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
Performance Comparison of Individual and Ensemble CNN Models for the Classification of Brain 18F-FDG-PET Scans.
Nobashi, T., Zacharias, C., Ellis, J. K., Ferri, V., Koran, M. E., Franc, B. L., … Davidzon, G. A. (2019). Performance Comparison of Individual and Ensemble CNN Models for the Classification of Brain 18F-FDG-PET Scans. Journal of Digital Imaging. -
Ga-68-RM2 PET/CT in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer
Iagaru, A., Baratto, L., Duan, H., Hatami, N., Mari, C., & Davidzon, G. (2019). Ga-68-RM2 PET/CT in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 46(SUPPL 1), S277–S278. -
Machine Learning to Detect Prostate Cancer Recurrence using F-18-Fluciclovine PET
Davidzon, G. A., Lee, J., Yang, H., Song, H., Harrison, C., & Iagaru, A. (2019). Machine Learning to Detect Prostate Cancer Recurrence using F-18-Fluciclovine PET. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 46(SUPPL 1), S65–S66. -
Prospective evaluation of F-18-DCFPyL in Patients with Biochemically Recurrent Prostate Cancer
Iagaru, A., Duan, H., Song, H., Harrison, C., Guja, K., Franc, B., … Davidzon, G. (2019). Prospective evaluation of F-18-DCFPyL in Patients with Biochemically Recurrent Prostate Cancer. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 46(SUPPL 1), S593. -
Fungal endocarditis resembling primary cardiac malignancy in a patient with B-cell ALL with culture confirmation.
Girod, B. J., Guja, K. E., Davidzon, G., Chan, F., Zucker, E., Franc, B. L., … Aparici, C. M. (2020). Fungal endocarditis resembling primary cardiac malignancy in a patient with B-cell ALL with culture confirmation. Radiology Case Reports, 15(2), 117–19. -
Human biodistribution and radiation dosimetry of [18F]DASA-23, a PET probe targeting pyruvate kinase M2.
Beinat, C., Patel, C. B., Haywood, T., Shen, B., Naya, L., Gandhi, H., … Gambhir, S. S. (2020). Human biodistribution and radiation dosimetry of [18F]DASA-23, a PET probe targeting pyruvate kinase M2. European Journal of Nuclear Medicine and Molecular Imaging. -
Evaluation of Toxicity in Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumors (NET)
Duan, H., Girod, B., Ninatti, G., Ferri, Kunz, P., Fisher, G., … Aparici, M. C. (2020). Evaluation of Toxicity in Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumors (NET). NEUROENDOCRINOLOGY, 110, 252. -
Extrahepatic 68Ga-DOTATATE-Avid Tumor Volume and Serum Chromogranin A Predict Short-Term Outcome of 177Lu-DOTATATE in Late-Stage Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Song, H., Kunz, P., Franc, B., Moradi, F., Fisher, G., Aparici, M. C., … Davidzon, G. (2020). Extrahepatic 68Ga-DOTATATE-Avid Tumor Volume and Serum Chromogranin A Predict Short-Term Outcome of 177Lu-DOTATATE in Late-Stage Metastatic Gastroenteropancreatic Neuroendocrine Tumors. NEUROENDOCRINOLOGY, 110, 274. -
Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy.
Nakamoto, R., Zaba, L. C., Rosenberg, J., Reddy, S. A., Nobashi, T. W., Davidzon, G., … Franc, B. L. (2020). Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy. European Journal of Nuclear Medicine and Molecular Imaging. -
Single institution experience with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET)
Duan, H., Ninatti, G., Girod, B., Ferri, V., Kunz, P. L., Fisher, G. A., … Mari, C. (2020). Single institution experience with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET). JOURNAL OF CLINICAL ONCOLOGY, 38(4). -
Application of Deep Learning to Predict Standardized Uptake Value Ratio and Amyloid Status on 18F-Florbetapir PET Using ADNI Data.
Reith, F., Koran, M. E., Davidzon, G., & Zaharchuk, G. (2020). Application of Deep Learning to Predict Standardized Uptake Value Ratio and Amyloid Status on 18F-Florbetapir PET Using ADNI Data. AJNR. American Journal of Neuroradiology. -
Generalization of deep learning models for ultra-low-count amyloid PET/MRI using transfer learning.
Chen, K. T., Schürer, M., Ouyang, J., Koran, M. E., Davidzon, G., Mormino, E., … Barthel, H. (2020). Generalization of deep learning models for ultra-low-count amyloid PET/MRI using transfer learning. European Journal of Nuclear Medicine and Molecular Imaging. -
Deep learning detection of prostate cancer recurrence with 18F-FACBC (fluciclovine, Axumin®) positron emission tomography.
Lee, J. J., Yang, H., Franc, B. L., Iagaru, A., & Davidzon, G. A. (2020). Deep learning detection of prostate cancer recurrence with 18F-FACBC (fluciclovine, Axumin®) positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging. -
Tau PET imaging with 18F-PI-2620 in aging and neurodegenerative diseases.
Mormino, E. C., Toueg, T. N., Azevedo, C., Castillo, J. B., Guo, W., Nadiadwala, A., … Chin, F. T. (2020). Tau PET imaging with 18F-PI-2620 in aging and neurodegenerative diseases. European Journal of Nuclear Medicine and Molecular Imaging. -
Imaging Characteristics and Diagnostic Performance of 2-deoxy-2-[18F]fluoro-D-Glucose PET/CT for Melanoma Patients Who Demonstrate Hyperprogressive Disease When Treated with Immunotherapy.
Nakamoto, R., C Zaba, L., Rosenberg, J., Arani Reddy, S., W Nobashi, T., Ferri, V., … Lewis Franc, B. (2020). Imaging Characteristics and Diagnostic Performance of 2-deoxy-2-[18F]fluoro-D-Glucose PET/CT for Melanoma Patients Who Demonstrate Hyperprogressive Disease When Treated with Immunotherapy. Molecular Imaging and Biology. -
INTERIM ANALYSIS RESULTS OF A PROSPECTIVE STUDY OF (68)GA-RM2 PET/MRI IN PATIENTS WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER AND NEGATIVE CONVENTIONAL IMAGING
Baratto, L., Song, H., Duan, H., Aparici, C. M., Hatami, N., Davidzon, G., … Iagaru, A. (2020). INTERIM ANALYSIS RESULTS OF A PROSPECTIVE STUDY OF (68)GA-RM2 PET/MRI IN PATIENTS WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER AND NEGATIVE CONVENTIONAL IMAGING. JOURNAL OF UROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
An unusual presentation of recurrent T cell lymphoma: angiocentric pattern of cutaneous uptake on [18F]FDG PET/CT.
Guja, K. E., Brown, R., Girod, B., Song, H., Harrison, C., Franc, B. L., … Aparici, C. M. (2020). An unusual presentation of recurrent T cell lymphoma: angiocentric pattern of cutaneous uptake on [18F]FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging. -
Obituary for Sanjiv Sam Gambhir, MD, PhD.
Davidzon, G., Franc, B., Mari Aparici, C., Moradi, F., Nguyen, J., & Iagaru, A. (2020). Obituary for Sanjiv Sam Gambhir, MD, PhD. Clinical Nuclear Medicine. -
Prospective evaluation of F-18-DCFPyL PET/CT in biochemically recurrent prostate cancer: Analysis of lesion localization and distribution.
Song, H., Duan, H., Harrison, C., Guja, K., Hatami, N., Franc, B. L., … Iagaru, A. (2020). Prospective evaluation of F-18-DCFPyL PET/CT in biochemically recurrent prostate cancer: Analysis of lesion localization and distribution. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
A pilot study of F-18-FSPG SiPM-based PET/CT in patients referred for exclusion of active cardiac sarcoidosis and negative or non-diagnostic F-18-FDG PET/CT
Duan, H., Hatami, N., Baratto, L., Davidzon, G., Aparici, C. M., Gambhir, S., … Iagaru, A. (2020). A pilot study of F-18-FSPG SiPM-based PET/CT in patients referred for exclusion of active cardiac sarcoidosis and negative or non-diagnostic F-18-FDG PET/CT. JOURNAL OF NUCLEAR MEDICINE, 61. -
Extrahepatic Ga-68-DOTATATE-Avid Tumor Volume and serum Chromogranin A Predict Short-Term Outcome of Lu-177-DOTATATE in Late-Stage Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Song, H., Kunz, P., Franc, B., Moradi, F., Fisher, G., Aparici, C. M., … Davidzon, G. (2020). Extrahepatic Ga-68-DOTATATE-Avid Tumor Volume and serum Chromogranin A Predict Short-Term Outcome of Lu-177-DOTATATE in Late-Stage Metastatic Gastroenteropancreatic Neuroendocrine Tumors. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Toxicity identification and evaluation of peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NETs)
Duan, H., Girod, B., Ninatti, G., Ferri, V., Kunz, P., Fisher, G., … Aparici, C. M. (2020). Toxicity identification and evaluation of peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NETs). JOURNAL OF NUCLEAR MEDICINE, 61. -
Visual Read Protocols for Clinicians Analyzing 18F-PI-2620 tau PET/MRI Images
Koran, M. E., Shams, S., Adams, P., Toueg, T., Azevedo, C., Hall, J., … Mormino, E. (2020). Visual Read Protocols for Clinicians Analyzing 18F-PI-2620 tau PET/MRI Images. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Imaging characteristics and diagnostic performance of F-18-FDG PET/CT for melanoma patients who demonstrate hyperprogressive disease when treated with immunotherapy
Nakamoto, R., Zaba, L., Rosenberg, J., Reddy, S., Nobashi, T., Davidzon, G., … Franc, B. (2020). Imaging characteristics and diagnostic performance of F-18-FDG PET/CT for melanoma patients who demonstrate hyperprogressive disease when treated with immunotherapy. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy
Nakamoto, R., Zaba, L., Rosenberg, J., Reddy, S., Nobashi, T., Davidzon, G., … Franc, B. (2020). Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
PSMA-and GRPR-targeted PET: Preliminary Results in Patients with Biochemically Recurrent Prostate Cancer
Baratto, L., Duan, H., Hatami, N., Song, H., Davidzon, G., Franc, B., … Iagaru, A. (2020). PSMA-and GRPR-targeted PET: Preliminary Results in Patients with Biochemically Recurrent Prostate Cancer. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Ga-68-PSMA-11 PET/MR Imaging before prostatectomy: correlation with surgical pathology and two-year follow up
Moradi, F., Baratto, L., Duan, H., Hatami, N., Davidzon, G., Sonn, G., & Iagaru, A. (2020). Ga-68-PSMA-11 PET/MR Imaging before prostatectomy: correlation with surgical pathology and two-year follow up. JOURNAL OF NUCLEAR MEDICINE, 61. -
Ga-68-RM2 PET/CT in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer
Baratto, L., Duan, H., Hatami, N., Aparici, C. M., Davidzon, G., & Iagaru, A. (2020). Ga-68-RM2 PET/CT in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer. JOURNAL OF NUCLEAR MEDICINE, 61. -
Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET): A single institution experience in the USA
Duan, H., Ferri, V., Kunz, P. L., Fisher, G. A., Moradi, F., Davidzon, G. A., … Mari, C. A. (2020). Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET): A single institution experience in the USA. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 47(SUPPL 1), S468–S469. -
Evaluation of toxicity in peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET)
Duan, H., Ferri, V., Kunz, P. L., Fisher, G. A., Moradi, F., Davidzon, G. A., … Mari, C. A. (2020). Evaluation of toxicity in peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET). EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 47(SUPPL 1), S471–S472. -
Prospective Single Institution Study of F18-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer: An Analysis of Lesions Detection and Localization
Iagaru, A., Song, H., Duan, H., Harrison, C., Guja, K., Hatami, N., … Davidzon, G. (2020). Prospective Single Institution Study of F18-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer: An Analysis of Lesions Detection and Localization. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 47(SUPPL 1), S171. -
Association of CSF Biomarkers with Hippocampal-dependent Memory in Preclinical Alzheimer Disease.
Trelle, A. N., Carr, V. A., Wilson, E. N., Swarovski, M. S., Hunt, M. P., Toueg, T. N., … Mormino, E. C. (2021). Association of CSF Biomarkers with Hippocampal-dependent Memory in Preclinical Alzheimer Disease. Neurology. -
True ultra-low-dose amyloid PET/MRI enhanced with deep learning for clinical interpretation.
Chen, K. T., Toueg, T. N., Koran, M. E., Davidzon, G., Zeineh, M., Holley, D., … Zaharchuk, G. (2021). True ultra-low-dose amyloid PET/MRI enhanced with deep learning for clinical interpretation. European Journal of Nuclear Medicine and Molecular Imaging. -
The Clinical Utility of 18F-Fluciclovine PET/CT in Biochemically Recurrent Prostate Cancer: an Academic Center Experience Post FDA Approval.
Nakamoto, R., Harrison, C., Song, H., Guja, K. E., Hatami, N., Nguyen, J., … Iagaru, A. (2021). The Clinical Utility of 18F-Fluciclovine PET/CT in Biochemically Recurrent Prostate Cancer: an Academic Center Experience Post FDA Approval. Molecular Imaging and Biology. -
Artificial Intelligence for Optimization and Interpretation of PET/CT and PET/MR Images.
Zaharchuk, G., & Davidzon, G. (2021). Artificial Intelligence for Optimization and Interpretation of PET/CT and PET/MR Images. Seminars in Nuclear Medicine, 51(2), 134–42. -
Prognostic value of bone marrow metabolism on pretreatment 18F-FDG PET/CT in patients with metastatic melanoma treated with anti-PD-1 therapy.
Nakamoto, R., Zaba, L. C., Liang, T., Reddy, S. A., Davidzon, G., Aparici, C. M., … Franc, B. L. (2021). Prognostic value of bone marrow metabolism on pretreatment 18F-FDG PET/CT in patients with metastatic melanoma treated with anti-PD-1 therapy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase 3, Multicenter Study.
Morris, M. J., Rowe, S. P., Gorin, M. A., Saperstein, L., Pouliot, F., Josephson, D. Y., … Pachynski, R. K. (2021). Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase 3, Multicenter Study. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
A prospective study of Ga-68-RM2 PET/MRI in patients with biochemically recurrent prostate cancer and negative conventional imaging.
Baratto, L., Song, H., Duan, H., Aparici, C. M., Davidzon, G., Moradi, F., … Iagaru, A. (2020). A prospective study of Ga-68-RM2 PET/MRI in patients with biochemically recurrent prostate cancer and negative conventional imaging. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer.
Baratto, L., Song, H., Duan, H., Hatami, N., Bagshaw, H., Buyyounouski, M., … Iagaru, A. (2021). PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
A single institution experience with peptide receptor radionuclide therapy (PRRT) in non-midgut neuroendocrine tumors (NETs)
Duan, H., Ferri, Fisher, G., Shaheen, S., Davidzon, G., Moradi, F., … Mari, A. C. (2021). A single institution experience with peptide receptor radionuclide therapy (PRRT) in non-midgut neuroendocrine tumors (NETs). JOURNAL OF NEUROENDOCRINOLOGY, 33, 181. -
A single institution experience with peptide receptor radionuclide therapy (PRRT) in advanced pheochromocytoma and paraganglioma
Duan, H., Ferri, Fisher, G., Shaheen, S., Davidzon, G., Moradi, F., … Mari, A. C. (2021). A single institution experience with peptide receptor radionuclide therapy (PRRT) in advanced pheochromocytoma and paraganglioma. JOURNAL OF NEUROENDOCRINOLOGY, 33, 180. -
Multi-task weak supervision enables anatomically-resolved abnormality detection in whole-body FDG-PET/CT.
Eyuboglu, S., Angus, G., Patel, B. N., Pareek, A., Davidzon, G., Long, J., … Lungren, M. P. (2021). Multi-task weak supervision enables anatomically-resolved abnormality detection in whole-body FDG-PET/CT. Nature Communications, 12(1), 1880. -
Increasing Diversity in Radiology and Molecular Imaging: Current Challenges.
Fite, B. Z., Hinostroza, V., States, L., Hicks-Nelson, A., Baratto, L., Kallianos, K., … Daldrup-Link, H. E. (2021). Increasing Diversity in Radiology and Molecular Imaging: Current Challenges. Molecular Imaging and Biology. -
Renal and Hepatotoxicity of Peptide Receptor Radionuclide Therapy (PRRT) - A Single Institution Experience
Duan, H., Ferri, V., Kunz, P., Davidzon, G., Nguyen, J., Moradi, F., … Aparici, C. M. (2021). Renal and Hepatotoxicity of Peptide Receptor Radionuclide Therapy (PRRT) - A Single Institution Experience. PANCREAS, 50(3), 456–457. -
Single Institution Experience With Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET)
Duan, H., Ferri, V., Kunz, P., Davidzon, G., Nguyen, J., Moradi, F., … Aparici, C. M. (2021). Single Institution Experience With Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET). PANCREAS, 50(3), 456. -
Hematotoxicity of Peptide Receptor Radionuclide Therapy (PRRT) - A Single Institution Experience
Duan, H., Ferri, V., Kunz, P., Davidzon, G., Moradi, F., Nguyen, J., … Aparici, C. M. (2021). Hematotoxicity of Peptide Receptor Radionuclide Therapy (PRRT) - A Single Institution Experience. PANCREAS, 50(3), 456. -
Dual-Time Ga-68-PSMA-11 Imaging for Biochemically Recurrent Prostate Cancer Using LYSO and SiPM-Based Detectors PET/CT
Park, S., Hatami, N., Baratto, L., Yohannan, T., Davidzon, G., & Iagaru, A. (2018). Dual-Time Ga-68-PSMA-11 Imaging for Biochemically Recurrent Prostate Cancer Using LYSO and SiPM-Based Detectors PET/CT. JOURNAL OF NUCLEAR MEDICINE, 59. -
Initial Experience with a New PET/CT System Using SiPM Detectors
Park, S., Baratto, L., Hatami, N., Davidzon, G., Srinivas, S., Gambhir, S., & Iagaru, A. (2017). Initial Experience with a New PET/CT System Using SiPM Detectors. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 44, S426. -
First Experience with Fast Imaging Using Discovery MI PET/CT
Sonni, I., Park, S., Baratto, L., Hatami, N., Davidzon, G., Srinivas, S., … Iagaru, A. H. (2017). First Experience with Fast Imaging Using Discovery MI PET/CT. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 44, S304. -
SiPM PET/CT vs. Standard PET/CT: A Pilot Study Comparing Semi-Quantitative Measurements in Normal Tissues and Lesions
Baratto, L., Park, S., Hatami, N., Davidzon, G., Srinivas, S., Gambhir, S. S., & Iagaru, A. (2017). SiPM PET/CT vs. Standard PET/CT: A Pilot Study Comparing Semi-Quantitative Measurements in Normal Tissues and Lesions. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 44, S431. -
Improved Pulmonary Nodule Detection Using a Next Generation F-18-FDG PET Imaging System
Park, S., Baratto, L., Hatami, N., Davidzon, G., Srinivas, S., Nair, V., & Iagaru, A. (2017). Improved Pulmonary Nodule Detection Using a Next Generation F-18-FDG PET Imaging System. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 44, S311–S312. -
Comparison of four different imaging response criteria in patients with Hodgkin and non-Hodgkin lymphoma using PET/CT
Davidzon, G., & Mittra, E. (2011). Comparison of four different imaging response criteria in patients with Hodgkin and non-Hodgkin lymphoma using PET/CT. JOURNAL OF NUCLEAR MEDICINE, 52. -
Detection of bone marrow disease in lymphoma using computer aided segmentation and analysis
Davidzon, G., Peng, Z., Anand, V., Zhou, X., & Quon, A. (2012). Detection of bone marrow disease in lymphoma using computer aided segmentation and analysis. JOURNAL OF NUCLEAR MEDICINE, 53. -
Lung Fdg Uptake On Pet-CT Is Decreased In Patients With COPD
Nair, V. S., Guo, H., Davidzon, G., Zirlinger, A., Chooljian, D. M., Mittra, E., & Rubin, D. (2014). Lung Fdg Uptake On Pet-CT Is Decreased In Patients With COPD. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 189. -
Results of a Prospective Trial to Compare 68Ga-DOTA-TATE with SiPM-Based PET/CT vs. Conventional PET/CT in Patients with Neuroendocrine Tumors.
Baratto, L., Toriihara, A., Hatami, N., Aparici, C. M., Davidzon, G., Levin, C. S., & Iagaru, A. (2021). Results of a Prospective Trial to Compare 68Ga-DOTA-TATE with SiPM-Based PET/CT vs. Conventional PET/CT in Patients with Neuroendocrine Tumors. Diagnostics (Basel, Switzerland), 11(6). -
Hematotoxicity of Peptide Receptor Radionuclide Therapy (PRRT) - A Single Institution Experience
Duan, H., Ferri, V., Kunz, P., Davidzon, G., Moradi, F., Nguyen, J., … Aparici, C. M. (2021). Hematotoxicity of Peptide Receptor Radionuclide Therapy (PRRT) - A Single Institution Experience. PANCREAS. LIPPINCOTT WILLIAMS & WILKINS. -
Renal and Hepatotoxicity of Peptide Receptor Radionuclide Therapy (PRRT) - A Single Institution Experience
Duan, H., Ferri, V., Kunz, P., Davidzon, G., Nguyen, J., Moradi, F., … Aparici, C. M. (2021). Renal and Hepatotoxicity of Peptide Receptor Radionuclide Therapy (PRRT) - A Single Institution Experience. PANCREAS. LIPPINCOTT WILLIAMS & WILKINS. -
Single Institution Experience With Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET)
Duan, H., Ferri, V., Kunz, P., Davidzon, G., Nguyen, J., Moradi, F., … Aparici, C. M. (2021). Single Institution Experience With Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET). PANCREAS. LIPPINCOTT WILLIAMS & WILKINS. -
Low-count whole-body PET with deep learning in a multicenter and externally validated study.
Chaudhari, A. S., Mittra, E., Davidzon, G. A., Gulaka, P., Gandhi, H., Brown, A., … Jadvar, H. (2021). Low-count whole-body PET with deep learning in a multicenter and externally validated study. NPJ Digital Medicine, 4(1), 127. -
A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2 Induced Glycolytic Reprogramming in Glioblastoma.
Beinat, C., Patel, C. B., Haywood, T., Murty, S., Naya, L., Castillo, J. B., … Gambhir, S. S. (2021). A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2 Induced Glycolytic Reprogramming in Glioblastoma. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Author Correction: Low-count whole-body PET with deep learning in a multicenter and externally validated study.
Chaudhari, A. S., Mittra, E., Davidzon, G. A., Gulaka, P., Gandhi, H., Brown, A., … Jadvar, H. (2021). Author Correction: Low-count whole-body PET with deep learning in a multicenter and externally validated study. NPJ Digital Medicine, 4(1), 139. -
PROSPECTIVE STUDY OF (68)GA-RM2 PET/MRI IN PATIENTS WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER AND NEGATIVE CONVENTIONAL IMAGING
Baratto, L., Song, H., Duan, H., Moradi, F., Davidzon, G., & Iagaru, A. (2021). PROSPECTIVE STUDY OF (68)GA-RM2 PET/MRI IN PATIENTS WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER AND NEGATIVE CONVENTIONAL IMAGING. JOURNAL OF UROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
PROSPECTIVE EVALUATION OF F-18-DCFPYL PET/CT IN BIOCHEMICALLY RECURRENT PROSTATE CANCER: ANALYSIS OF F-18-DCFPYL UPTAKE IN POSSIBLE EXTRA-PELVIC OLIGOMETASTASES
Song, H., Nguyen, J., Moradi, F., Aparici, C. M., Franc, B., Davidzon, G., & Iagaru, A. (2021). PROSPECTIVE EVALUATION OF F-18-DCFPYL PET/CT IN BIOCHEMICALLY RECURRENT PROSTATE CANCER: ANALYSIS OF F-18-DCFPYL UPTAKE IN POSSIBLE EXTRA-PELVIC OLIGOMETASTASES. JOURNAL OF UROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Six Recurrent Amyloid-Related Imaging Abnormality Episodes in a Patient Treated With Aducanumab.
Hall, J. N., Mormino, E., Ng, A., Boumis, A., Gaudioso, J. L., Davidzon, G. A., & Sha, S. J. (2021). Six Recurrent Amyloid-Related Imaging Abnormality Episodes in a Patient Treated With Aducanumab. JAMA Neurology. -
68Ga-PSMA11 PET/CT for biochemically recurrent prostate cancer: Influence of dual-time and PMT- vs SiPM-based detectors.
Duan, H., Baratto, L., Hatami, N., Liang, T., Mari Aparici, C., Davidzon, G. A., & Iagaru, A. (2021). 68Ga-PSMA11 PET/CT for biochemically recurrent prostate cancer: Influence of dual-time and PMT- vs SiPM-based detectors. Translational Oncology, 15(1), 101293. -
Initial Clinical Evaluation of [F-18]DASA-23, a PET Imaging Tracer for Evaluation of Aberrantly Expressed Pyruvate Kinase M2 in Glioblastoma
Beinat, C., Patel, C., Haywood, T., Naya, L., Castillo, J., Shen, B., … Gambhir, S. (2021). Initial Clinical Evaluation of [F-18]DASA-23, a PET Imaging Tracer for Evaluation of Aberrantly Expressed Pyruvate Kinase M2 in Glioblastoma. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
A Pilot Study of68Ga-PSMA11 PET/MRI and68GaRM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer
Duan, H., Ferri, V., Ghanouni, P., Daniel, B., Hatami, N., Davidzon, G., … Iagaru, A. (2021). A Pilot Study of68Ga-PSMA11 PET/MRI and68GaRM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Perfusion Only Scans with and without SPECT/CT in the Era of COVID-19
Zhang, R., Moradi, F., Aparici, C. M., Davidzon, G., Nguyen, J., Iagaru, A., & Franc, B. (2021). Perfusion Only Scans with and without SPECT/CT in the Era of COVID-19. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
A Pilot Study of Ga-68-PSMA11 and Ga-68-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High Intensity Focused Ultrasound (HIFU) Therapy
Duan, H., Ghanouni, P., Hatami, N., Davidzon, G. A., Aparici, C. M., Thong, A., … Iagaru, A. (2021). A Pilot Study of Ga-68-PSMA11 and Ga-68-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High Intensity Focused Ultrasound (HIFU) Therapy. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. SPRINGER. -
A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer
Duan, H., Ferri, V., Ghanouni, P., Daniel, B., Hatami, N., Davidzon, G. A., … Iagaru, A. (2021). A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. SPRINGER. -
Phenotypic Heterogeneity among GBA p.R202X Carriers in Lewy Body Spectrum Disorders.
Napolioni, V., Fredericks, C. A., Kim, Y., Channappa, D., Khan, R. R., Kim, L. H., … Greicius, M. D. (1800). Phenotypic Heterogeneity among GBA p.R202X Carriers in Lewy Body Spectrum Disorders. Biomedicines, 10(1). -
Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up
Duan, H., Ferri, V., Fisher, G. A., Shaheen, S., Davidzon, G. A., Iagaru, A., & Aparici, C. M. (2022). Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up. ONCOLOGIST. -
Evaluation of interim Dotatate-PET after two cycles of Peptide Receptor Radionuclide Therapy (PRRT) in neuroendocrine tumors (NET)
Duan, H., Song, H., Ferri, Fisher, G., Shaheen, S., Shah, J., … Mari, A. C. (2022). Evaluation of interim Dotatate-PET after two cycles of Peptide Receptor Radionuclide Therapy (PRRT) in neuroendocrine tumors (NET). JOURNAL OF NEUROENDOCRINOLOGY. WILEY. -
68Ga-PSMA-11 PET/MRI in patients with newly diagnosed intermediate or high-risk prostate adenocarcinoma: PET findings correlate with outcomes after definitive treatment.
Moradi, F., Duan, H., Song, H., Davidzon, G. A., Chung, B. I., Thong, A. E., … Iagaru, A. (2022). 68Ga-PSMA-11 PET/MRI in patients with newly diagnosed intermediate or high-risk prostate adenocarcinoma: PET findings correlate with outcomes after definitive treatment. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
Correlation of 68Ga-RM2 PET with Post-Surgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer.
Duan, H., Baratto, L., Fan, R. E., Soerensen, S. J., Liang, T., Chung, B. I., … Iagaru, A. (2022). Correlation of 68Ga-RM2 PET with Post-Surgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up.
Duan, H., Ferri, V., Fisher, G. A., Shaheen, S., Davidzon, G. A., Iagaru, A., & Mari Aparici, C. (2022). Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up. The Oncologist. -
Peptide Receptor Radionuclide Therapy (PRRT) in Advanced Pheochromocytoma and Paraganglioma From a Single Institution Experience
Duan, H., Ferri, V., Fisher, G. A., Shaheen, S., Davidzon, G. A., Moradi, F., … Aparici, C. M. (2022). Peptide Receptor Radionuclide Therapy (PRRT) in Advanced Pheochromocytoma and Paraganglioma From a Single Institution Experience. PANCREAS. LIPPINCOTT WILLIAMS & WILKINS. -
Modified PROMISE Criteria for Standardized Interpretation of GRPR-targeted PET
Duan, H., Davidzon, G. A., Moradi, F., Liang, T., & Iagaru, A. (2022). Modified PROMISE Criteria for Standardized Interpretation of GRPR-targeted PET. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. SPRINGER. -
A Pilot Study of Ga-68-PSMA11 and Ga-68-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High Intensity Focused Ultrasound (HIFU) Therapy
Duan, H., Ghanouni, P., Daniel, B., Rosenberg, J., Davidzon, G. A., Aparici, C. M., … Iagaru, A. (2022). A Pilot Study of Ga-68-PSMA11 and Ga-68-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High Intensity Focused Ultrasound (HIFU) Therapy. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. SPRINGER. -
A Pilot Study of Ga-68-PSMA11 and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer
Duan, H., Ghanouni, P., Daniel, B., Rosenberg, J., Thong, A., Sonn, G. A., … Iagaru, A. (2022). A Pilot Study of Ga-68-PSMA11 and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. SPRINGER. -
Head-to-head Comparison of a Conventional or CZT-based SPECT/CT with a Next Generation Multidetector CZT-based SPECT/CT System
Duan, H., Ferri, V., Castaneda, P., Visser, T., Luong, K., Davidzon, G. A., … Iagaru, A. (2022). Head-to-head Comparison of a Conventional or CZT-based SPECT/CT with a Next Generation Multidetector CZT-based SPECT/CT System. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. SPRINGER. -
Multi-tracer PET Imaging Using Deep Learning: Applications in Patients with High-Grade Gliomas
Wardak, M., Hooper, S. M., Schiepers, C., Chen, W., Aparici, C. M., Davidzon, G. A., … Gambhir, S. S. (2022). Multi-tracer PET Imaging Using Deep Learning: Applications in Patients with High-Grade Gliomas. PREDICTIVE INTELLIGENCE IN MEDICINE (PRIME 2022). SPRINGER INTERNATIONAL PUBLISHING AG. -
A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High Intensity Focused Ultrasound (HIFU) Therapy.
Duan, H., Ghanouni, P., Daniel, B., Rosenberg, J., Davidzon, G. A., Mari Aparici, C., … Iagaru, A. (2022). A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High Intensity Focused Ultrasound (HIFU) Therapy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer's disease.
Wilson, E. N., Young, C. B., Ramos Benitez, J., Swarovski, M. S., Feinstein, I., Vandijck, M., … Andreasson, K. I. (2022). Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer's disease. Alzheimer's Research & Therapy, 14(1), 172. -
A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer.
Duan, H., Ghanouni, P., Daniel, B., Rosenberg, J., Thong, A., Kunder, C., … Iagaru, A. (2022). A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
Hong Song, Heying Duan, Caitlyn Harrison, Kip Guja, Negin Hatami, Judy Nguyen, Benjamin Franc, Farshad Moradi, Carina Mari Aparici, Guido Davidzon, Sandy Srinivas and Andrei lagaru
Song, H., Duan, H., Harrison, C., Guja, K., Hatami, N., Nguyen, J., … Iagaru, A. (2022). Hong Song, Heying Duan, Caitlyn Harrison, Kip Guja, Negin Hatami, Judy Nguyen, Benjamin Franc, Farshad Moradi, Carina Mari Aparici, Guido Davidzon, Sandy Srinivas and Andrei lagaru. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Results of First Interim Analysis of 68Ga-NeoB and 68Ga-PSMA R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer
Duan, H., Song, H., Davidzon, G., Moradi, F., & Iagaru, A. (2022). Results of First Interim Analysis of 68Ga-NeoB and 68Ga-PSMA R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Multi-task Deep Learning for Cerebrovascular Disease Classification and MRI-to-PET Translation
Hussein, R., Zhao, M. Y., Shin, D., Guo, J., Chen, K. T., Armindo, R. D., … Zaharchuk, G. (2022). Multi-task Deep Learning for Cerebrovascular Disease Classification and MRI-to-PET Translation. 2022 26TH INTERNATIONAL CONFERENCE ON PATTERN RECOGNITION (ICPR). IEEE. -
SPECT at the speed of PET: a feasibility study of CZT-based whole-body SPECT/CT in the post 177Lu-DOTATATE and 177Lu-PSMA617 setting.
Song, H., Ferri, V., Duan, H., Aparici, C. M., Davidzon, G., Franc, B. L., … Iagaru, A. (2023). SPECT at the speed of PET: a feasibility study of CZT-based whole-body SPECT/CT in the post 177Lu-DOTATATE and 177Lu-PSMA617 setting. European Journal of Nuclear Medicine and Molecular Imaging. -
Reductions in synaptic marker SV2A in early-course Schizophrenia.
Yoon, J. H., Zhang, Z., Mormino, E., Davidzon, G., Minzenberg, M. J., Ballon, J., … Chin, F. T. (2023). Reductions in synaptic marker SV2A in early-course Schizophrenia. Journal of Psychiatric Research, 161, 213–217. -
Predicting FDG-PET Images From Multi-Contrast MRI Using Deep Learning in Patients With Brain Neoplasms.
Ouyang, J., Chen, K. T., Duarte Armindo, R., Davidzon, G. A., Hawk, K. E., Moradi, F., … Zaharchuk, G. (2023). Predicting FDG-PET Images From Multi-Contrast MRI Using Deep Learning in Patients With Brain Neoplasms. Journal of Magnetic Resonance Imaging : JMRI. -
ChatGPT in nuclear medicine and radiology: lights and shadows in the AI bionetwork
Laudicella, R., Davidzon, G. A., Dimos, N., Provenzano, G., Iagaru, A., & Bisdas, S. (2023). ChatGPT in nuclear medicine and radiology: lights and shadows in the AI bionetwork. CLINICAL AND TRANSLATIONAL IMAGING. -
Modified PROMISE criteria for standardized interpretation of gastrin-releasing peptide receptor (GRPR)-targeted PET.
Duan, H., Davidzon, G. A., Moradi, F., Liang, T., Song, H., & Iagaru, A. (2023). Modified PROMISE criteria for standardized interpretation of gastrin-releasing peptide receptor (GRPR)-targeted PET. European Journal of Nuclear Medicine and Molecular Imaging. -
Generative Adversarial Network-Enhanced Ultra-Low-Dose [18F]-PI-2620 tau PET/MRI in Aging and Neurodegenerative Populations.
Chen, K. T., Tesfay, R., Koran, M. E., Ouyang, J., Shams, S., Young, C. B., … Zaharchuk, G. (2023). Generative Adversarial Network-Enhanced Ultra-Low-Dose [18F]-PI-2620 tau PET/MRI in Aging and Neurodegenerative Populations. AJNR. American Journal of Neuroradiology.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx »
- Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN) »
- Quantitative 13N-Ammonia Cardiac Rest/Stress Digital PET/CT »
- A Pilot Study of 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer »
- [18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers »
Practice Locations
Nuclear Medicine and Molecular Imaging Stanford, CA
Stanford, CA
Nuclear Medicine and Molecular Imaging
300 Pasteur Drive, 2nd Floor, C21
Stanford , CA 94305
Make An Appointment More Clinic Information » Getting Here »Important Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referring Physicians.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- View referral status
- Access medical records